TY - JOUR
T1 - A retrospective review
AU - Wang, Qunfeng
AU - Chen, Fang
AU - Jiang, Depeng
AU - Kabani, Amin
AU - Sokoro, Abdul Razaq A.H.
N1 - Publisher Copyright:
© American Society for Clinical Pathology, 2020.
PY - 2020
Y1 - 2020
N2 - Objectives: To review the utilization of prostate-specific antigen (PSA) testing in Winnipeg, a major Canadian city, and to compare PSA testing rates between Winnipeg and Calgary, another major Canadian city of comparable size. Methods: PSA testing results were reviewed by year and age group. We focused our studies in years 2011 and 2016, for which census demographic data are available. Results: In Winnipeg, the PSA testing rates (patients with one or two PSA tests divided by the male population) showed a declining trend over years from 2008 to 2017. For almost all age groups, PSA testing rates in 2016 decreased in comparison to those in 2011. For age older than 40 years, the relative percentage decreases were 14% to 20%. In 2011, Winnipeg PSA testing rates were consistently higher than those in Calgary for all age groups. For age older than 40 years, the relative percentage differences were 36% to 50%. In addition, 41% and 40% of patients in Winnipeg who underwent PSA testing were younger than 50 years or older than 69 years in 2011 and 2016, respectively. Conclusions: PSA testing utilization may be falling short of optimal rates. There is a need to reinforce the optimal use of clinical recommendations.
AB - Objectives: To review the utilization of prostate-specific antigen (PSA) testing in Winnipeg, a major Canadian city, and to compare PSA testing rates between Winnipeg and Calgary, another major Canadian city of comparable size. Methods: PSA testing results were reviewed by year and age group. We focused our studies in years 2011 and 2016, for which census demographic data are available. Results: In Winnipeg, the PSA testing rates (patients with one or two PSA tests divided by the male population) showed a declining trend over years from 2008 to 2017. For almost all age groups, PSA testing rates in 2016 decreased in comparison to those in 2011. For age older than 40 years, the relative percentage decreases were 14% to 20%. In 2011, Winnipeg PSA testing rates were consistently higher than those in Calgary for all age groups. For age older than 40 years, the relative percentage differences were 36% to 50%. In addition, 41% and 40% of patients in Winnipeg who underwent PSA testing were younger than 50 years or older than 69 years in 2011 and 2016, respectively. Conclusions: PSA testing utilization may be falling short of optimal rates. There is a need to reinforce the optimal use of clinical recommendations.
KW - Prostate cancer detection
KW - Prostate-specific antigen
KW - PSA test
UR - https://www.scopus.com/pages/publications/85089126954
U2 - 10.1093/AJCP/AQAA003
DO - 10.1093/AJCP/AQAA003
M3 - Article
C2 - 32003789
AN - SCOPUS:85089126954
SN - 0002-9173
VL - 153
SP - 776
EP - 780
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
IS - 6
ER -